if herpes doesn't work they will sell the company no doubt. astellas will buy them at 20 million premium to there cash which is 50 mil. so only 20 percent risk. if the result is good it will be near 1 to 1.3 dollar which is 10 to 12 times. that's the reality why coletas working his aress day and night trying to scare people selling there shares for pennies
3.5 million dollar cash investment. is a big vote of confident. I think there is great news underway
that means its cleared for clinic. a trial will start soon. I hope they have a partner for it.
maybe astellas that could explain there favorable anti fungal deal
I can only identify two things that make wall street favor fibrogen, first is that they have strong partners which is a big help in phase 3. second I think most investor believe that fibrogen drug is safer but that's is yet to be verified. I think the set back akebia had last October is due to investor believing that there pills are not safe due to some mortality in there phase 2 a result which may be unrelated to the drug. however I think the right thing is that akebia partner the drug in japan and Europe prior to phase 3 which im betting they will do. if that happens I think we can see new high for the stock.
so why the huge difference in valuation compared to fibrogen. is it the fibrosis drug they have ? I understand that they are ahead of Akebia in there blood drug however I don't see them advanced with a long shot or is there drug better than Akebia drug ?
when Oi will receive the proceeds from PT sale ?
how much ?
did they say what they will do with it ? pay debt ?
how come its so undervalued. I assume they are getting around 8 billion in cash ?